July 1, 1999
View Full PaperGenetic Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic Leukemia
Key Points
Key points are not available for this paper at this time.
Abstract
D ESPITE ITS well-known sensitivity to anthracyclines,1-51 acute promyelocytic leukemia (APL) was catalogued until the late 1980s as one of the most rapidly fatal human tumors, with the majority of patients dying early of intractable hemorrhage or disease relapse.62 Two major research
Cite This Study
Lo‐Coco et al. (Thu,) studied this question.